Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Bart Staels, Anne Rubenstrunk, Benoit Noel et al. · Hepatology · 2013
UNLABELLED: Nonalcoholic fatty liver disease (NAFLD) covers a spectrum of liver damage ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. To date, no pharmacological treatment is approved for NAFLD/NASH. Here, we report on preclinical and clinical data with GFT505, a novel dual peroxisome proliferator-activated receptor alpha/delta (PPAR-α/δ) agonist. In the rat, GFT505 concentrated in the liver with limited extrahepatic exposure and underwent extensive enterohepatic cycling. The efficacy of GFT505 was assessed in animal models of NAFLD/NASH and liver fibrosis (Western diet [WD]-fed human apolipoprotein E2 [hApoE2] transgenic mice, methionine- and choline-deficient diet-fed db/db mice, and CCl4 -induced fibrosis in rats). GFT505 demonstrated liver-protective effects on steatosis, inflammation, and fibrosis. In addition, GFT505 improved liver dysfunction markers, decreased hepatic lipid accumulation, and inhibited proinflammatory (interleukin-1 beta, tumor necrosis factor alpha, and F4/80) and profibrotic (transforming growth factor beta, tissue inhibitor of metalloproteinase 2, collagen type I, alpha 1, and collagen type I, alpha 2) gene expression. To determine the role of PPAR-α-independent mechanisms, the effect of GFT505 was assessed in hApoE2 knock-in/PPAR-α knockout mice. In these mice, GFT505 also prevented WD-induced liver steatosis and inflammation, indicating a contribution of PPAR-α-independent mechanisms. Finally, the effect of GFT505 on liver dysfunction markers was assessed in a combined analysis of four phase II clinical studies in metabolic syndrome patients. GFT505 treatment decreased plasma concentrations of alanine aminotransferase, gamma-glutamyl transpeptidase, and alkaline phosphatase. CONCLUSION: The dual PPAR-α/δ agonist, GFT505, is a promising liver-targeted drug for treatment of NAFLD/NASH. In animals, its protective effects are mediated by both PPAR-α-dependent and -independent mechanisms.
Cited by 411 works. doi:10.1002/hep.26461
Authors
- Bart Staels
- Anne Rubenstrunk
- Géraldine Rigou
- Philippe Delataille
- Lesley J. Millatt
- Morgane Baron
- Anne Tailleux
- Dean W. Hum
- Vlad Ratziu
- Bertrand Cariou
- Rémy Hanf
References
- The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
- Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis
- A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
- Improved Nonalcoholic Steatohepatitis After 48 Weeks of Treatment With the Ppar–γ Ligand Rosiglitazone
- Ursodeoxycholic Acid or Clofibrate in the Treatment of Non–Alcohol–Induced Steatohepatitis: A Pilot Study
- Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis
- Alternative M2 Activation of Kupffer Cells by PPARδ Ameliorates Obesity-Induced Insulin Resistance
- Sorting out the roles of PPAR in energy metabolism and vascular homeostasis